[Clinicopathological features and prognosis of synchronous bilateral breast cancers].

Objective: To study the clinicopathologic characteristics and relevant factors affecting prognosis of patients with synchronous bilateral breast cancer. Methods: The clinical data, pathologic characteristics and immunohistochemical expression characteristics of 151 patients with synchronous bilateral breast cancers diagnosed in Peking Union Medical College Hospital from 2008 to 2018 were collected and analyzed. The factors affecting the prognosis were analyzed by Log rank test, Kaplan-Meier survival analysis, Cox regression and other methods. Results: Synchronous bilateral breast cancer cases accounted for 1.2% (151/12 239) of all breast cancer patients in the same period, and 14.6% (22/151) had a family history. The patients' age range was 22-88 years, mainly female, with a mean survival of 42.5 months. There were 106 patients with synchronous bilateral invasive breast cancers, 6 patients with synchronous bilateral breast cancer in situ, and 39 patients with unilateral invasive breast cancer and unilateral breast cancer in situ. In synchronous bilateral invasive breast cancers, the histological type was mainly non-specific type (84.9%, 180/212), the histological grade was mainly Grade 2 (60.8%,129/212), the TNM stage was mainly stage Ⅰ (50.5%, 107/212), the tumor size was mainly T1 (68.9%, 146/212), and the regional lymph node was mainly N0 (61.8%, 131/212). The molecular subtypes were mainly Luminal A-like (38.1%, 75/197) and Luminal B-like (43.7%, 86/197); ER (78.2%, 154/197) and PR (72.1%,142/197)were mainly positive, and HER2 was mainly negative (91.9%, 181/197). There were 85 (80.2%) patients and 75 (70.8%) patients with the same histological type and histological grade on both sides, respectively. The concordance of tumor size T stage and the regional lymph nodes N stage were 58.5% (62/106) and 55.7% (59/106), respectively. The concordance of molecular subtype was 54.9% (50/91), and the concordance of ER, PR, HER2 and Ki-67 were 83.5% (76/91), 76.9% (70/91), 89.0% (81/91) and 59.3% (54/91), respectively. The expression of ER and PR in synchronous bilateral invasive breast cancer was significantly correlated with prognosis (P<0.05). Conclusions: Among patients with synchronous bilateral breast cancers, bilateral invasive breast cancer is the most common, the prognosis is the worst, and the pathologic characteristics of bilateral breast cancer tend to be consistent. The expression of ER and PR in synchronous bilateral invasive breast cancer is significantly correlated with prognosis, that is, best for bilateral ER-positive patients, worst for bilateral ER-negative patients, and intermediate for unilateral ER-positive patients, thus suggesting the importance of ER and PR detection in synchronous bilateral invasive breast cancers.目的： 探讨同时性双侧乳腺癌的临床病理特征及影响预后的相关因素，特别是双侧浸润性乳腺癌的组织病理学特点及两侧表达情况。 方法： 收集分析2008—2018年北京协和医院确诊的151例同时性双侧乳腺癌患者的临床资料、病理学特征及免疫组织化学表达特点，采用Log rank检验、Kaplan-Meier生存分析、Cox回归等方法分析影响预后的因素。 结果： 同时性双侧乳腺癌病例数占同期乳腺癌病例数的1.2%（151/12 239），其中14.6%（22/151）的患者有乳腺癌家族史。患者年龄范围22~88岁，以女性为主，平均生存期42.5个月。106例为双侧浸润性癌，6例为双侧原位癌，39例为单侧浸润性癌、单侧原位癌。在同时性双侧浸润性乳腺癌中，组织学类型以非特殊型为主（84.9%，180/212），组织学分级以中分化为主（60.8%，129/212），TNM分期以Ⅰ期为主（50.5%，107/212）；肿瘤大小以T1为主（68.9%，146/212），区域淋巴结以N0为主（61.8%，131/212）。分子分型以Luminal A样型（38.1%，75/197）和Luminal B样型（43.7%，86/197）为主；ER（78.2%，154/197）和PR（72.1%，142/197）以阳性表达为主，HER2以阴性为主（91.9%，181/197）。双侧组织学类型和组织学分级一致者分别为85例（80.2%）和75例（70.8%），肿瘤大小T分期和区域淋巴结N分期一致率分别为58.5%（62/106）和55.7%（59/106），分子分型一致率为54.9%（50/91），ER、PR、HER2和Ki-67表达一致率分别为83.5%（76/91）、76.9%（70/91）、89.0%（81/91）和59.3%（54/91）。其中双侧乳腺癌ER、PR的表达情况与预后有显著相关性（P<0.05）。 结论： 同时性双侧乳腺癌患者中，双侧浸润性乳腺癌患者数量最多、预后最差，两侧乳腺癌病理学特征倾向于一致；双侧乳腺癌ER、PR表达情况与预后有显著相关性，即ER双侧阳性者预后最好，双侧阴性者预后最差，单侧阳性者预后介于两者之间，提示对同时性双侧浸润性乳腺癌均进行雌、孕激素受体检测的重要性。.